GTG.AX - Genetic Technologies Limited

ASX - ASX Delayed price. Currency in AUD
0.012
+0.001 (+9.09%)
At close: 4:10PM AEST
Stock chart is not supported by your current browser
Previous close0.011
Open0.011
Bid0.012 x 0
Ask0.012 x 0
Day's range0.011 - 0.012
52-week range0.006 - 0.021
Volume12,448,591
Avg. volume5,888,271
Market cap30.529M
Beta2.12
PE ratio (TTM)N/A
EPS (TTM)-0.003
Earnings date1 Mar. 2016 - 5 Mar. 2016
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.25
  • GlobeNewswire12 hours ago

    Genetic Technologies Limited Invited by Representatives of the Hainan Government to Discuss Market Entry into China

    MELBOURNE, Australia, Aug. 21, 2018-- Representatives of the Hainan Government- Hainan Ecological Smart City Group, a Chinese industrial park development & operations company have formally invited Genetic ...

  • GlobeNewswire5 days ago

    Genetic Technologies Announces Proposed Joint Venture with Beijing Zishan Health Consultancy Limited

    Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has signed a Heads of Agreement (Agreement) with Beijing Zishan Health Consultancy Limited (Zishan). Zishan will take on the functions of sales, account management, marketing and promotion of GTG’s genetic risk assessment products for the Chinese market.

  • GlobeNewswire13 days ago

    Genetic Technologies Secures A$20 Million Equity Placement Facility

    Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a A$20 million Equity Placement Facility (the “Facility”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment management firm, to strengthen the Company’s funding position. Under the Facility, Kentgrove Capital may provide the Company with up to A$20 million of equity capital in a series of individual placements of up to $1 million (or a higher amount by mutual agreement) over the next 20 months.

  • GlobeNewswire19 days ago

    Genetic Technologies Formalises Strategic Alliance with Blockchain Global

    Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Framework Agreement (“Agreement”) with Blockchain Global Limited ACN 601 628 497 (“BCG”).

  • GlobeNewswire22 days ago

    Genetic Technologies Announces Appointment of Swisstec as Non-Exclusive Asian Distributor

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Swisstec Health Analytics Ltd. (“Swisstec”).  This agreement grants Swisstec the right to explore opportunities to deliver GTG’s genetic screening tests to hospital networks in Asia.

  • Genetic Technologies Stock Up on Genetic Test Update
    Market Realistlast month

    Genetic Technologies Stock Up on Genetic Test Update

    Today, Genetic Technologies (GENE) was trading over 70% higher than yesterday’s closing price of $1.09. The stock jumped ~72.5% in premarket trading. The stock price and volumes rose on the news of the company’s on-track breast cancer and colorectal cancer risk assessment tests, slated for release in October.

  • GlobeNewswirelast month

    Genetic Technologies Limited Announces Expansion of Genetic Risk Assessment Tests and October Launch of New Breast Cancer and Colorectal Cancer Tests

    MELBOURNE, Australia, July 16, 2018-- Genetic Technologies Limited, a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today that ...

  • GlobeNewswire2 months ago

    Genetic Technologies Announces Heads of Agreement with Swisstec

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Heads of Agreement with Swisstec Health Analytics Ltd. (“Swisstec”) to work together over the next 30 days to finalise a Proposed Joint Venture (PJV) to establish a new Company, (“JV Company”). The JV Company will enable both companies to collaborate to develop a service platform using blockchain technology that will provide a marketplace for medical services and personalised health management, and will also facilitate data management and AI-based services to promote better patient outcomes.

  • GlobeNewswire2 months ago

    Genetic Technologies Announces Binding Project Shivom Agreement

    Project Shivom to provide GTG access to a significant pool of data, particularly related to the Indian population. GTG, through access to the Indian population data to modify its risk assessment kits as well as to develop new Indian specific tests or products, including tests related to diabetes and other disease, based on opportunity and areas of need.